Blood Pressure Medications

Overview / What Is It

Blood pressure management is one of the most critical but underappreciated safety considerations in AAS and hormone research contexts. Exogenous androgens elevate blood pressure through multiple concurrent mechanisms — renin-angiotensin-aldosterone system (RAAS) activation, sodium and water retention, erythrocytosis-driven blood viscosity increases, and left ventricular hypertrophy (LVH) with long-term use. Unmanaged hypertension in this context significantly amplifies cardiovascular risk.

Two drug classes dominate research in this space: ACE inhibitors (angiotensin-converting enzyme inhibitors, with Lisinopril being the most prescribed) and ARBs (angiotensin receptor blockers, with Telmisartan being particularly interesting for reasons beyond BP control). Both classes work on the RAAS pathway but at different points, and the choice between them has practical implications for AAS researchers.

Telmisartan stands out among antihypertensives for an additional mechanism: it is a partial agonist at PPAR-γ (peroxisome proliferator-activated receptor gamma) — the same nuclear receptor targeted by thiazolidinedione diabetes drugs. This gives Telmisartan metabolic benefits (improved insulin sensitivity, increased adiponectin, favorable lipid effects) beyond simple BP reduction, making it a research-relevant choice for subjects with AAS-induced metabolic changes.

Mechanism of Action

Lisinopril (ACE inhibitor): Blocks angiotensin-converting enzyme, preventing the conversion of angiotensin I to angiotensin II. Angiotensin II is the primary vasoconstrictor in the RAAS cascade — blocking its formation reduces vascular tone and aldosterone-mediated sodium retention. A secondary effect: ACE also breaks down bradykinin, so ACE inhibition causes bradykinin accumulation. Bradykinin is vasodilatory and cardioprotective, but its accumulation in airway tissue causes the classic ACE inhibitor cough (dry, persistent, seen in 5-20% of users).

Telmisartan (ARB): Acts downstream of ACE — directly blocks the AT1 receptor where angiotensin II binds. Same endpoint as ACE inhibitors (reduced vasoconstriction and aldosterone release) without bradykinin accumulation, so no cough. Telmisartan's additional PPAR-γ partial agonism (unique among ARBs) activates nuclear receptors in adipocytes, increasing adiponectin secretion, improving glucose uptake, and favorably altering fat distribution — effects demonstrated in multiple head-to-head trials against other ARBs.

Clinical Protocol Context

Antihypertensive medications represent the most extensively studied drug class in cardiovascular medicine, with landmark trials defining treatment targets and drug selection across multiple populations. ALLHAT (2002, JAMA) — the largest antihypertensive trial (42,418 patients) — compared chlorthalidone, amlodipine, and lisinopril over 4.9 years. SPRINT (2015, NEJM) fundamentally shifted target blood pressure to <120 mmHg systolic for high-risk patients. ACCOMPLISH (Jamerson et al., 2008, NEJM) demonstrated superiority of ACE inhibitor + calcium channel blocker over ACE inhibitor + thiazide. In AAS research contexts, antihypertensive management of AAS-induced hypertension is a critical harm reduction consideration.

Dosing & Administration

Telmisartan: 40mg once daily for 2-4 weeks → assess response → 80mg once daily if inadequate. Maximum: 80mg/day. Once-daily dosing (longest half-life among ARBs at ~24 hours). Can be taken with or without food. No food-drug timing restrictions.

Lisinopril: 5mg once daily → 10mg → 20mg → 40mg (max). Hypertensive doses typically 10-40mg/day. Start low to avoid first-dose hypotension — take initially at bedtime. Once-daily dosing. No food restrictions.

Amlodipine (calcium channel blocker — frequently co-used): 5mg once daily → 10mg/day. Often added as a second agent when RAAS blockade alone is insufficient. Effective combination: ARB + CCB (e.g., Telmisartan + Amlodipine) or ACE + CCB (e.g., Lisinopril + Amlodipine). Target BP in research contexts: <130/80 (AHA 2017 Stage 1 hypertension threshold). If BP exceeds 180/110, research protocols involving cardiovascular stress should be suspended until controlled.

Bloodwork & Monitoring

Home BP monitoring is the primary tracking tool — a calibrated upper-arm cuff, measured in the morning before medications and at rest, provides more clinically meaningful data than single office readings. Log average of 3 morning readings per week.

• Basic Metabolic Panel (BMP): Baseline and 4-6 weeks after initiation — checks potassium (hyperkalemia risk with RAAS blockers), creatinine (acceptable 20-30% rise; >30% or doubling = assess for renal artery stenosis), sodium, glucose.
• Potassium: RAAS blockers reduce aldosterone → potassium retention. Target K+ <5.0 mEq/L. Risk increases if combined with K+ supplements, NSAIDs, or other K+-sparing agents.
• eGFR/Creatinine: Renal function check at baseline, 4-6 weeks, then every 6 months. RAAS blockers are renoprotective long-term but cause initial eGFR dip (by reducing intraglomerular pressure).
• Hematocrit: AAS-induced erythrocytosis is a BP driver — managing hematocrit (<52%) directly contributes to BP control. Monitor hematocrit at each bloodwork check.
• Echocardiography: For long-term AAS users — LVH assessment, wall thickness, diastolic function. Not routine but indicated with prolonged uncontrolled hypertension or duration >5 years of AAS use.

Side Effects & Risk Profile

Lisinopril: Cough (5-20%, bradykinin mechanism — dry, persistent, often worst at night). This is the primary reason to switch to an ARB. Angioedema (rare but potentially life-threatening — facial and airway swelling; absolute contraindication to re-challenge with any ACE inhibitor). Hyperkalemia (potassium elevation — monitor K+). First-dose hypotension (especially volume-depleted subjects — take first dose at bedtime). Renal impairment (contraindicated in bilateral renal artery stenosis).

Telmisartan: No cough (no bradykinin mechanism). Lower angioedema risk than ACE inhibitors. Same hyperkalemia, renal, and hypotension risk class as ACE inhibitors. Dizziness and headache common in first weeks. Teratogenic (Class D — avoid in pregnancy). Rare: back pain, sinusitis, pharyngitis.

Amlodipine (if added): Peripheral edema (ankle swelling — most common side effect, dose-dependent), headache, flushing. Gingival hyperplasia (rare). No metabolic side effects — considered metabolically neutral.

Drug Interactions

• AAS: Testosterone and anabolic steroids activate the RAAS directly and via fluid retention and erythrocytosis. BP medications directly counter these mechanisms. Telmisartan's PPAR-γ effect may partially complement AAS-induced insulin resistance.
• NSAIDs (ibuprofen, naproxen, aspirin >1g/day): Significantly reduce ACE inhibitor and ARB efficacy (inhibit prostaglandin-mediated renal vasodilation). Also increase acute kidney injury risk in combination. Avoid if possible; use paracetamol for pain management instead.
• Potassium supplements and K+-sparing diuretics: Additive hyperkalemia risk with RAAS blockers — avoid unless K+ is monitored closely.
• Tadalafil: Additive hypotensive effect — combination is used deliberately for dual BP management in some research protocols but requires monitoring for symptomatic hypotension.
• GLP-1 agonists (Semaglutide/Tirzepatide): Weight loss-induced BP reduction may allow antihypertensive dose reduction over time — monitor and adjust accordingly.
• Lithium: ACE inhibitors increase lithium levels — psychiatric medication interaction to flag.

Harm Reduction

• Do not start AAS research protocols with uncontrolled hypertension (>140/90). Baseline BP control is a prerequisite.
• If BP exceeds 150/100 during a cycle, reduce dose or pause — do not continue and "wait it out."
• If Lisinopril causes persistent cough, switch to Telmisartan rather than discontinuing antihypertensive therapy entirely.
• Avoid NSAIDs during RAAS blocker use — ibuprofen is commonly used post-injection and will counteract the antihypertensive and potentially precipitate AKI.
• Don't stop BP medications abruptly — rebound hypertension can occur, particularly with clonidine (not covered here but common co-use).
• Hematocrit management (phlebotomy at >52%) is BP management — the two are not separate. High hematocrit means thick blood, increased vascular resistance, and elevated BP that no medication fully compensates for.
• Cardiovascular events don't give warnings — regular monitoring is non-negotiable, not optional.

Research & Literature

The cardiovascular evidence base for RAAS blockers is among the most robust in all of pharmacology. The ONTARGET trial (Telmisartan vs Ramipril, 25,000+ subjects) demonstrated Telmisartan's non-inferiority to the gold-standard ACE inhibitor Ramipril for cardiovascular outcomes, with better tolerability. TRANSCEND extended this evidence to ACE-intolerant subjects. The HOPE study (Ramipril, Heart Outcomes Prevention Evaluation) established ACE inhibitors' cardiovascular protection beyond BP reduction — a landmark 2000 NEJM publication.

For Telmisartan's PPAR-γ activity: Benson et al. (Hypertension 2004) documented insulin sensitization independent of BP reduction. Multiple comparison trials vs other ARBs (Irbesartan, Valsartan) confirm the PPAR-γ effect is unique to Telmisartan. In the AAS context: Kicman (British Journal of Pharmacology 2008) provides the most comprehensive review of AAS-induced cardiovascular mechanisms, including RAAS activation as a key hypertensive pathway. Hartgens & Kuipers (Sports Med 2004) covers the cardiovascular risk profile of AAS comprehensively.